PMID- 38020293
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 26
IP  - 6
DP  - 2023 Dec
TI  - Efficacy and safety of hepatic arterial infusion chemotherapy combined with 
      immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced 
      hepatocellular carcinoma: A systematic review and meta‑analysis.
PG  - 534
LID - 10.3892/ol.2023.14121 [doi]
LID - 534
AB  - At present, hepatic arterial infusion chemotherapy (HAIC) for the treatment of 
      hepatocellular carcinoma (HCC) is often applied to patients who are not suitable 
      or are unwilling to undergo surgical treatment. However, to the best of our 
      knowledge, the efficacy and safety of HAIC combined with immune checkpoint 
      inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in HCC have not been 
      fully demonstrated. Published studies involving the treatment of patients with 
      HCC with HAIC, ICIs and TKIs were searched from public databases, including 
      PubMed, Embase, the Cochrane Library and Sinomed. Efficacy and safety data for 
      each study, including progression-free survival (PFS), overall survival (OS) and 
      adverse events (AEs) were collected. The present study included 17 treatment 
      groups from 15 studies, including 1,987 patients with HCC in the systematic 
      review. The target population was dominated by those unsuitable for surgical 
      treatment, with Barcelona Clinic Liver Cancer stage B or C, Eastern Cooperative 
      Oncology Group performance status </=2 and Child-Pugh score A or B. The results 
      showed that the longest estimated median PFS (95% CI) in the HAIC + ICI/TKI 
      therapy group (group C) was 9.37 months (95% CI, 6.81-11.93); in the HAIC therapy 
      group (group B) was 7.45 months (95% CI, 6.45-8.46); and in the ICIs + other 
      systemic therapies group (group A) was 5.92 months (95% CI, 5.31-6.54). There was 
      no significant difference in the expected OS among the three groups, which may be 
      because OS events were not reached in numerous studies during the follow-up time. 
      The incidence of treatment-related adverse effects, such as increased AST [14/221 
      (6.33%)], increased ALT [13/221 (5.88%)], and decreased platelet count [13/221 
      (5.88%)], was not significantly increased in group C when compared with groups A 
      or B (P>0.05). In conclusion, the effectiveness of HAIC + ICI/TKI for the 
      treatment of advanced HCC was better than that of ICIs + other systemic therapies 
      or HAIC alone. In addition, the incidence of AEs above grade 3 was not 
      significantly higher compared with that in the other treatment groups, and the 
      safety profile was good.
CI  - Copyright: (c) Li et al.
FAU - Li, Zixiong
AU  - Li Z
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Xu, Yanping
AU  - Xu Y
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Qu, Wenshu
AU  - Qu W
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Zhu, Yan
AU  - Zhu Y
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Guo, Ying
AU  - Guo Y
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
FAU - Liu, Xiufeng
AU  - Liu X
AD  - Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, 
      Jiangsu 210002, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20231030
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10655037
OTO - NOTNLM
OT  - adverse events
OT  - hepatic arterial infusion chemotherapy
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - tyrosine kinase inhibitors
COIS- The authors declare that they have no competing interests.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/10/30
CRDT- 2023/11/29 14:41
PHST- 2023/06/05 00:00 [received]
PHST- 2023/10/13 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 14:41 [entrez]
PHST- 2023/10/30 00:00 [pmc-release]
AID - OL-26-6-14121 [pii]
AID - 10.3892/ol.2023.14121 [doi]
PST - epublish
SO  - Oncol Lett. 2023 Oct 30;26(6):534. doi: 10.3892/ol.2023.14121. eCollection 2023 
      Dec.